Vaccines, Biological and Influenza, and Pharmaceutical (related to Opioid use disorders and overdose)

The 269-C1 multi-award vehicle provides access to vaccines, biologicals, influenza vaccines, and pharmaceuticals with a primary focus on opioid use disorder and overdose management. Procurable items under this vehicle include immunization products such as diphtheria, tetanus, and pertussis vaccines, as well as specialized pharmaceuticals including immunomodulating drugs based on tyrosine and kinase inhibitors, hyaluronic acid-based products, and opioid-related therapeutic agents. This vehicle is designed to support public health initiatives, disease prevention programs, and substance abuse treatment through access to critical vaccine and pharmaceutical supplies.

The 269-C1 contract is administered by CPA Contract Management and covers the State of Texas. The contract was awarded on June 8, 2018, with a completion date of June 8, 2027, providing a nine-year period of performance. This multiple award vehicle operates under a miscellaneous drugs and pharmaceuticals procurement structure, enabling authorized state and local entities throughout Texas to obtain vaccines, serums, toxoids, and related pharmaceutical products through pre-negotiated contracts with eligible prime contractors.